Crescita Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -30.93%. Crescita Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 0.95.
Crescita Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -32.56%.
Crescita Therapeutics ROE % Adjusted to Book Value Related Terms
Crescita Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Crescita Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescita Therapeutics ROE % Adjusted to Book Value Chart
TSX:CTX vs ZTS: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescita Therapeutics ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Crescita Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -32.56% mean?
Crescita Therapeutics (TSX:CTX) has a ROE % Adjusted to Book Value of -32.56% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' ROE % Adjusted to Book Value too high?
Crescita Therapeutics' current ROE % Adjusted to Book Value is -32.56%. Overall, Crescita Therapeutics has a GF Score™ of 20/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' ROE % Adjusted to Book Value compare to ZTS?
Crescita Therapeutics' ROE % Adjusted to Book Value of -32.56% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current ROE % Adjusted to Book Value is -32.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (TSX:CTX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.68, compared to a current price of C$0.79 — trading 16.2% above its estimated fair value. The current ROE % Adjusted to Book Value is -32.56%. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current ROE % Adjusted to Book Value is -32.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crescita Therapeutics (TSX:CTX) Overvalued in 2026?
Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued.
The current stock price of C$0.79 is trading 16.2% above its estimated GF Value™ of C$0.68.
GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:CTX:
ROE % Adjusted to Book Value: -32.56%
GF Value™: C$0.68 vs. price of C$0.79 (16.2% above fair value)
No single metric tells the full story. See the TSX:CTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score
Get the complete analysis for TSX:CTX
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CTX has been successfully added to your 
